UNSPSC 51284604: Imipenem

This classification denotes a beta-lactam antibiotic with the molecular formula C12H17N3O4S.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 71OTZ9ZE0A, chemically known as 1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 6-(1-hydroxyethyl)-3-((2-((iminomethyl)amino)ethyl)thio)-7-oxo-, (5r-(5-alpha,6-alpha(r*)))- but generally known as imipenem, which bears US NIH Compound Identifier 47317. European Medicines Agency schedules Imipenem in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08151MIG.

UNSPSC 51284604 Imipenem is a Commodity code that nominally identifies a single antibiotic pharmaceutical product, yet recent state and local solicitations show little activity specifically targeting imipenem procurement. The code appears underutilized or misaligned with current buying patterns in state and local health procurement, which instead focus on broader pharmaceutical categories, medical supplies, and pharmacy benefit management arrangements. State and local governments are actively procuring generic multi-source pharmaceuticals, over-the-counter products, medical and first aid supplies for emergency response, and naloxone through dedicated programs, but imipenem does not surface as a distinct procurement line item in recent posted opportunities. The absence of targeted imipenem solicitations suggests that state and local buyers typically acquire this and similar antibiotics through broader pharmaceutical contracts, cooperative purchasing alliances, or standing agreements with wholesalers rather than as a standalone commodity acquisition.

The most relevant recent activity under pharmaceutical procurement appears in cooperative purchasing and health agency initiatives across multiple states. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP on January 20, 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers to state and local facilities including Oregon, with an effective date of July 1, 2026. The Texas Health and Human Services Commission issued an RFI on April 3, 2026 exploring direct-to-manufacturer prescription programs. The City of Tampa's Fire Department Rescue Division solicited medical and first aid supplies via ITB 26-P-00145 (due March 13, 2026) as a $700,000 sheltered-market opportunity for certified Small Local Business Enterprises. Seminole County, Florida solicited naloxone and drug deactivation systems via IFB 60459723LAS (due July 26, 2023). State departments, county health systems, and city emergency services remain the primary issuing bodies, with cooperative purchasing mechanisms serving multiple jurisdictions simultaneously. Imipenem procurement, if occurring, likely routes through these broader pharmaceutical or emergency-supply contracts rather than discrete solicitations naming the drug by commodity code.